Market Analysis
Part of Retail investment and business change
Evaluating acquisitions through documented business changes
Trace an acquisition from control to documented operating changes while keeping division results within their limits.
Wesfarmers’ move into Australian Pharmaceutical Industries (API) shows how to separate an announced offer from documented ownership and later business changes. Wesfarmers offered $687 million for API in 2021; Wesfarmers Health says it formed as a division in 2022 with the acquisition of API. Later disclosures name portfolio changes, but do not state a stand-alone API return.
Establish the acquisition boundary
On 12 July 2021, Wesfarmers offered $687 million, or $1.38 a share in cash, for API. API’s largest shareholder, Washington H. Soul Pattinson, had granted Wesfarmers a call option over its 19.3 per cent stake. Treat these as offer terms and transaction context, not proof of the final consideration or completion date.
Wesfarmers Health says it was formed as a Wesfarmers division in 2022 with the acquisition of API and brands including Priceline Pharmacy and Clear Skincare. This records the acquisition, but does not state the exact date control passed or the final consideration.
Under AASB 3, the acquisition date is when the buyer obtains control; it is generally the closing date but can be earlier or later. Check Wesfarmers’ acquisition accounting for the control date, consideration, assets and liabilities acquired, and goodwill. Those entries record the combination, not its strategic success.
Record changes over time
Wesfarmers Health says its business has expanded its footprint through further acquisitions in digital health and medical aesthetics. Its portfolio list includes Priceline Pharmacy, API, SILK Laser Clinics, Clear Skincare and InstantScripts; the list alone does not date each addition or establish which changes followed the API acquisition.
On 12 June 2023, API, a wholly owned subsidiary of Wesfarmers, agreed to buy InstantScripts for approximately $135 million. The announcement said InstantScripts would become part of Wesfarmers Health. Record this as an announced acquisition, not as evidence here of its completion or realised benefits.
| Documented item | What it can establish | What it cannot establish alone |
|---|---|---|
| Completion or control record | A dated reporting boundary | Future return |
| Acquisition accounting | Recognised consideration, assets, liabilities and goodwill | Successful integration |
| Segment report | Performance of the defined segment | The original target’s stand-alone contribution after integration |
| Operating update | Changes to stores, range, systems or service | That the deal caused all later growth |
Wesfarmers’ 2026 Full-year results is a named later reporting document to check for its reported divisional or segment boundary and results. Wesfarmers Health is identified as a division, but the stated facts give no Health revenue or earnings figure and no stand-alone API contribution. Do not treat a division-level result as an isolated return on API.
What each disclosure can and cannot establish about the API acquisition
- Completion or control record
- Establishes a dated reporting boundary
- Completion or control record
- Cannot establish future return
- Acquisition accounting
- Recognises consideration, assets, liabilities and goodwill
- Acquisition accounting
- Cannot establish successful integration
- Segment report
- Shows performance of the defined segment
- Segment report
- Cannot show the original target’s stand-alone contribution after integration
- Operating update
- Documents changes to stores, range, systems or service
- Operating update
- Cannot prove the deal caused all later growth
Test the claimed benefit
The InstantScripts announcement said the acquisition would add a presence in telehealth, align with Wesfarmers Health’s digital health focus and offer opportunities to use its pharmacy and Clear Skincare networks. Treat these as intended benefits; the announcement gives no quantified measure or period for realised synergies.
Where later reporting separates the acquired operation’s results from other acquisitions, costs or investment, compare those measures with the stated rationale. If it does not, avoid attributing divisional growth or margin changes to API alone.
A goodwill balance or the absence of an impairment does not prove success. Impairment disclosures address accounting carrying amounts; they are not a complete measure of the buyer’s economic return.
Conclude at the disclosed level
The disclosures establish that Wesfarmers acquired API and formed Wesfarmers Health as a division in 2022; they also document subsequent portfolio expansion and the 2023 InstantScripts agreement. They do not state API’s precise control date, final consideration, stand-alone post-acquisition results or invested capital.
Conclude at the level the reporting supports: the acquisition occurred and the division’s portfolio changed, but a precise return on API remains unresolved without stand-alone cash flows and invested capital.
